Levodopa skin patch for Parkinson’s treatment

Skin patch to continuously delivery levodopa treat Parkinson’s disease is underway.

The new skin patch developed by NeuroDerm is designed to maintain concentration of the anti-Parkinson’s medication levodop in a continuous manner for improving the treatment outcome.

Levodopa is currently the most effective drug for Parkinson’s disease.

The experimental levodopa patch code-named ND0611 increases levodopa bioavailability and extends its effects by administering a novel pharmaceutical.

Studies in animals using the levodapa patch found that it modified levodopa’s efficacy by increasing levodopa plasma half-life and activity period.

The patch also helped in maintaining levodopa plasma concentrations in a typical therapeutic range besides extending dopaminergic stimulation in the brain.

Levodopa patch’s mode of action involves an under-exploited levodopa metabolic pathway and has the potential for markedly improving clinical benefits from levodopa.

This Phase 1 study was conducted in healthy volunteers with the purpose of measuring the safety and tolerability of ND0611 at different doses.

Further analysis will be completed to determine the pharmacokinetic profile of levodopa in plasma.

The company expects to present the results of this phase 1 study in the second half of 2010.

“The completion of this first step in the clinical development of ND0611 marks an important milestone in the path to develop a new therapeutic alternative for Parkinson’s disease patients,” stated Oded S. Lieberman, PhD, NeuroDerm’s chairman and CEO.

While constant levodopa plasma concentrations achieved through continuous levodopa infusion have been shown to bring significant benefit to Parkinson’s patients, these options are generally impractical.

In contrast, ND0611 may offer a new treatment alternative that can be widely adopted for chronic control of the most common problems affecting Parkinson’s disease.

NeuroDerm is an emerging pharmaceutical company that develops therapeutic dermal patches for the treatment of CNS diseases.

NeuroDerm’s technology is based on proprietary reformulations of well established oral drugs whose low bio-availability is the major impediment to better efficacy. Besides ND0611, NeuroDerm is developing ADD, ADHD, schizophrenia and Alzheimer’s disease. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.

Parkinson’s disease is a progressive disorder of the nervous system that affects movement. It develops gradually, often starting with a barely noticeable tremor in just one hand.

The symptoms of Parkinson’s disease can vary from person to person. Tremor, slowed motion, rigid muscles, impaired posture and balance, loss of automatic movements, speech changes, dementia are some of the most common symptoms.

Levodopa is the most effective Parkinson’s drug, which is a natural substance in the body. When taken by mouth in pill form, it passes into the brain and is converted to dopamine.


  This content has been Digiproved

Advertisements
This entry was posted in Healthcare. Bookmark the permalink.

3 Responses to Levodopa skin patch for Parkinson’s treatment

  1. Pingback: Tweets that mention Levodopa skin patch for Parkinson’s treatment | Avantrasara -- Topsy.com

  2. Pingback: More Things That Annoy Me — My Parkinson's Disease Diary

  3. Pingback: More Things That Annoy Me | Parky Bill's PD Place

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s